PB1837: ADDITION OF A THIRD, NON-TARGETED, AGENT TO CYTARABINE- AND ANTHRACYCLINE-BASED INDUCTION CHEMOTHERAPY FOR ACUTE MYELOBLASTIC LEUKEMIA INCREASES COMPLETE REMISSIONS AND TREATMENT-RELATED MORTALITY

Detalles Bibliográficos
Autores principales: Pereira, M., Marques, G., Sarmento-Ribeiro, A.-B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430079/
http://dx.doi.org/10.1097/01.HS9.0000850200.50801.a5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430079/
http://dx.doi.org/10.1097/01.HS9.0000850200.50801.a5

Ejemplares similares